The FDA has approved biosimilars for: While many psoriasis medications come as injections, apremilast is a psoriasis treatment that comes as a pill. If you can’t take any of these medications or ...

"With the addition of a single-injection administration regimen, we are further expanding options and enhancing the treatment experience for individuals with moderate-to-severe plaque psoriasis ...

active psoriatic arthritis with coexistent plaque psoriasis and hidradenitis suppurativa. The single-injection 2 mL prefilled syringe and autoinjector for Bimzelx 320 mg is now available ...

and adults with chronic moderate-to-severe plaque psoriasis. In clinical trials, the most common adverse effect of this treatment was injection site reaction (ISR). This can occur in up to 49% of ...

On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

The Tremfya (trem-FYE-ah) ad starts with a woman in a dark room with patches of her skin seemingly on fire. Another woman ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

In studies, eight out of 10 patients with moderate-to-severe plaque-type ... prescribed to treat psoriasis. Biologics are a class of drugs usually administered by injection. These drugs alter ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...